23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
16:20 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Shield's Feraccru misses in Phase III for anemia

Shield Therapeutics plc (LSE:STX) reported that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in patients with non-dialysis-dependent chronic kidney disease (CKD). On the...
21:55 , Feb 5, 2018 |  BC Extra  |  Clinical News

Shield falls on Phase III Feraccru miss

Shield Therapeutics plc (LSE:STX) fell 65p (58%) to 47.50p on Monday after reporting that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in...
19:42 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Follow-on roundup: Ultragenyx, Adamas, Rocket

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Jan. 23 through the sale of 4.4 million shares at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Goldman Sachs...
22:56 , Jan 24, 2018 |  BC Extra  |  Financial News

Follow-on roundup

At least six companies priced follow-ons, raising more than $600 million total. Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Tuesday through the sale of 4.4 million shares at $57 in a...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
21:37 , Jan 5, 2018 |  BC Week In Review  |  Financial News

ProLung proposes $8.6M IPO

Lung cancer diagnostic play ProLung Inc. (Salt Lake City, Utah) proposed to raise up to $8.6 million in an IPO on NASDAQ underwritten by Maxim Group and Aegis Capital, according to an SEC filing on...
21:09 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Sun BioPharma withdraws follow-on

Cancer company Sun BioPharma Inc. (OTCQB:SNBPD) withdrew its follow-on on Dec. 28, 2017, citing market conditions. On Dec. 18, the company proposed to raise up to $11.5 million in the follow-on underwritten by Aegis Capital...
18:40 , Dec 22, 2017 |  BC Week In Review  |  Financial News

Sun BioPharma proposes $11.5M follow-on

On Dec. 18, cancer company Sun BioPharma Inc. (OTCQB:SNBPD) proposed to raise $11.5 million through the sale of 834,000 units in a follow-on underwritten by Aegis Capital and Lake Street Capital Markets. Each unit comprises...
19:36 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Ritter raises $23M in follow-on

Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) raised $23 million through the sale of 34.6 million class A units at $0.40 and 9,180 class B units at $1,000 in a follow-on underwritten by Aegis Capital. Each class A...